Impact of Different CRRT Modalities, Dosing Strategies, and Timing on Kidney Recovery and Prolonged Kidney Dysfunction

NCT07052617 | Not Yet Recruiting

• 2 other identifiers: 02/013AGCSOS2025
• Study Type: observational
• Target: 2,500
• Locations: 0 countries
• Sites: N/A

Brief Summary

KARMA study is a hospital-based research study looking at how different ways of delivering kidney support therapy (CRRT) affect patients who are critically ill. In some cases, the kidneys may temporarily stop working in very sick patients, and machines are used to filter the blood. This study is exploring whether the way the investigators use these machines - how early to start, how much treatment to give, and what type to choose - makes a difference in how well the kidneys recover. By learning from many hospitals and hundreds of patients, KARMA hopes to improve treatment choices and help patients regain their kidney function faster.

Conditions

Acute Kidney Disease; Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• Percentage of patients with AKD

  Percentage of patients with AKD divided by subgroups regarding AKI etiology

  90 days

Secondary Outcomes (1)

• Durations and severity of AKD, free days of CRRT and kidney recovery

  90 days

Interventions

Continuos renal replacement therapy DEVICE

Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

By analyzing the variation in therapeutic approaches across centers-including convection- and diffusion-based techniques, dose intensity, and initiation thresholds-KARMA study aims to identify best practices that promote renal recovery and reduce the transition to acute kidney disease. The study integrates clinical, biochemical, and outcome metrics to support a precision medicine framework in critical care nephrology and in critically ill patients with acute kidney injury.

You may qualify if:

• Acute kidney injury
• ICU administration

You may not qualify if:

• Pre-existing CKD (GFR \< 30 ml/min/1,73m2)
• Chronic dialysis-dependent end-stage renal failure

Sponsors & Collaborators

• Croatian Society for Organ Support: lead

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor, M.D., Ph.D.

Study Record Dates

• First Submitted: June 21, 2025
• First Posted: July 4, 2025
• Study Start: September 25, 2025
• Primary Completion (Estimated): September 25, 2026
• Study Completion (Estimated): December 25, 2026
• Last Updated: July 4, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: Start date: December 25, 2025 End date: October 25, 2026